Southern California-based Sienna Biopharmaceuticals filed for bankruptcy, which sent share prices tumbling more than 73 percent.
Genentech released full data from the company’s pivotal Phase III SAkuraStar trial of satralizumab as a monotherapy for NMOSD.
Biogen Inc. announced new data to support the consistent, long-term benefits of treatment with Tecfidera (dimethyl fumarate) over 10 years, as well as additional diroximel fumarate data that further characterize the tolerability profile of this investigational oral fumarate for relapsing multiple sclerosis.
A U.S. study suggests that annual costs of disease modifying treatments for multiple sclerosis more than quadrupled from 2006 to 2016 as several new, costly medicines entered the market.
Amgen will buy Celgene’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with the company’s $74 billion deal for Celgene by the end of 2019.
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
U.S. FDA Expands Regulatory Approvals for LEO Pharma’s Enstilar Foam and Taclonex Topical Suspension in Treatment of Plaque Psoriasis
LEO Pharma Inc announced the U.S. Food and Drug Administration expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. Additionally, the FDA approved Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension in the topical treatment of scalp and body plaque psoriasis in patients 12 years and older.
In a Phase III head-to-head trial, Janssen Pharmaceutical’s ponesimod stood up to Sanofi’s Aubagio (teriflunomide) in adults with relapsing multiple sclerosis.
Researchers with City University of New York and the Icahn School of Medicine at Mount Sinai identified specific biological differences between relapsing-remitting MS (RRMS) – in which patients often go into clinical remission – and progression MS, which has the potential to lead to new therapeutic approaches and diagnostic testing.